Why the study?
Tobacco use is a major cause of cardiovascular disease associated with endothelial dysfunction, but the association between smoking exposure and flow-mediated dilation required systematic investigation.
Does smoking exposure reduce endothelial function as evaluated by flow-mediated dilation (FMD) compared to non-smokers?
Does smoking exposure reduce endothelial function as evaluated by flow-mediated dilation (FMD) compared to non-smokers?
Smoking exposure, whether through conventional cigarettes or water pipes, significantly impairs endothelial function as measured by flow-mediated dilation, reinforcing the vascular risks of tobacco use.
BACKGROUND: Tobacco use is recognized as a major cause of cardiovascular disease, which is associated with endothelial dysfunction. Endothelial function is evaluated using flow-mediated dilation (FMD), which is a noninvasive method. This meta-analysis aimed to investigate the association between smoking exposure and endothelial function evaluated using FMD values. METHODS: We searched the PubMed, Embase, Web of Science, and Cochrane Library databases for cohort studies of smokers or passive smokers that used FMD to assess endothelial function. The primary outcome of the study was the change in the rate of FMD. The risk of bias was evaluated using the Cochrane Collaboration tool and Newcastle-Ottawa Scale. Further, the weighted mean difference was used to analyze the continuous data. RESULTS: Overall, 14 of 1426 articles were included in this study. The results of these articles indicated that smoking is a major cause of endothelial dysfunction and altered FMD; a pooled effect size of - 3.15 was obtained with a 95% confidence interval of (- 3.84, - 2.46). Notably, pregnancy status, Asian ethnicity, or health status did not affect heterogeneity. CONCLUSIONS: We found that smoking has a significant negative impact on FMD, and measures such as medication or education for smoking cessation may improve endothelial function and reduce the risk of cardiovascular disease. TRIAL REGISTRATION: The meta-analysis was registered with PROSPERO on April 5th, 2023 (CRD42023414654).
No takes yet. Share an insight, caveat, or question.
Jia et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: